Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 54: 1413-1414, 2008; 10.1373/clinchem.2008.110163
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hashimoto, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hashimoto, K.
(Clinical Chemistry. 2008;54:1413-1414.)
© 2008 American Association for Clinical Chemistry, Inc.


Editorials

CSF Serine Enantiomers and Glycine in the Study of Neurologic and Psychiatric Disorders

Kenji Hashimoto

Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan

Address correspondence to the author at: Division of Clinical Neuroscience Chiba University Center for Forensic Mental Health 1-8-1 Inohana Chiba 260-8670, Japan Fax +81-423-226-2150 E-mail hashimoto{at}faculty.chiba-u.jp

It was long believed that only the L-isomer of amino acids existed in mammals, and D–amino acids were regarded as laboratory artifacts and categorized as "unnatural" isomers. This term was widely used in textbooks of biochemistry. D–amino acids were known to be prominent in bacteria, and there were occasional reports of D–amino acids found in invertebrates (1). Hans Krebs accidentally discovered in kidney tissue an enzyme, D–amino acid oxidase (DAAO)1 , which recognized unnatural D–amino acids (but not their L-counterparts) (2). DAAO was found to degrade D–amino acids produced by bacteria from foods in the gut.

With the advance of chromatographic analysis techniques, small amounts of D–amino acids can now be measured in lower and higher animals, plants, and foods. By the use of 2-dimensional thin-layer chromatography and HPLC, Nagata et al. (3) found free D–amino acids, including D-serine, in kidney and blood of mutant mice lacking DAAO. Subsequently, Hashimoto and colleagues (4) demonstrated that D-serine was present in rat brain at high concentrations that were up to one-third those of L-serine, and that D-serine is heterogeneously distributed throughout rat brain with a pattern resembling that of the N-methyl D-aspartate (NMDA) subtype of glutamate receptors. Glutamate cannot activate the NMDA receptor in the absence of the coagonist glycine, and D-serine is up to 3 times more potent than glycine at the glycine site of the NMDA receptors. D-serine is likely to be the predominant endogenous ligand for the NMDA receptors in most areas of the brain. Although glycine serves this purpose in some sites, in most parts of the brain D-serine distribution matches that of NMDA receptors more than does glycine (5). D-Serine is produced by serine racemase from L-serine in the brain, and D-serine is metabolized by DAAO (5).

Column-switching HPLC with fluorescence detection (6) and HPLC with ultraviolet-visible detection (7) have been used for quantification of D- and L-serine. The former method includes precolumn fluorescence derivatization with 4-fluoro-7-nitro-2,1,3-benzoxadiazole and separation of the derivatives on a reversed-phase column and then on Sumichiral OA-2500 (S) Pirkle-type chiral columns (6). In this issue of Clinical Chemistry, Fuchs et al. (8) report 2 novel mass-spectrometric techniques for separation and quantification of D- and L-serine. To enable simultaneous determination of D-serine, L-serine, and glycine in small volumes of biological fluids, these authors developed stable isotope dilution assays using GC-MS and LC-MS. The GC-MS system they used is a nonchiral derivatization with chiral (Chirasil-L-val column) separation, and the LC-MS system is a chiral derivatization with Marfeys reagent and LC-MS analysis. Quantification limits for D-serine, L-serine, and glycine in cerebrospinal fluid (CSF) from human sample donors were 0.14, 0.44, and 0.14 µmol/L (GC-MS) and 0.20, 0.41, and 0.14 µmol/L (LC-MS), respectively. The concentrations of D-serine and L-serine in human CSF were also consistent with those previously reported by other groups (9)(10). Sample preparation time was 60 min for the LC-MS system, whereas it was approximately 6–8 h for the GC-MS system. The relatively short sample preparation time indicates that the LC-MS system is superior to the GC-MS system in its potential to be automated and used to perform high-throughput analysis.

The ability to measure CSF amino acids raises the question of whether CSF D-serine, L-serine, and glycine have enough potential clinical utility to warrant ongoing study. In patients with 3-phosphoglycerate dehydrogenase deficiency (OMIM 606879), a rare disorder of L-serine biosynthesis, CSF concentrations of D-serine, L-serine, and glycine are much lower than those in controls (11). In these patients postnatal L-serine supplementation normalized CSF D-serine, L-serine, and glycine as well as the clinical phenotype. Interestingly, in neonates whose mothers had undergone prenatal L-serine treatment, CSF concentrations of these amino acids at birth were near reference interval concentrations and the clinical phenotype was normal. Thus, it seems that L-serine biosynthesis, leading to D-serine synthesis and NMDA-receptor activation, is crucial for early neuronal development in humans (11). In the neonatal cerebellum of rodents, D-serine concentrations are high and peak at the time of granule cell migration, a finding that suggests that the principal role of D-serine in the developing cerebellum is to serve as a coagonist for NMDA receptor–dependent granule cell migration (12). Taken together, these findings suggest a pivotal role of both isomers of serine in normal and aberrant human brain development.

Alterations in blood or CSF concentrations of D- and L-serine have been found in patients with schizophrenia (9)(10)(13)(14), 3-phosphoglycerate-dehydrogenase deficiency, (11), and chronic pain(7). Furthermore, we reported increased glutamine:glutamate ratios in CSF of first-episode and drug-naive schizophrenic patients, suggesting that a dysfunction in the glutamate-glutamine cycle between neurons and glia may play a role in the pathophysiology of schizophrenia (15). Thus the work from multiple groups has provided evidence that serine enantiomers play important roles in neurological and psychological diseases.

In their current report Fuchs et al. confirm their previous finding (11) that in humans CSF concentrations of D-serine, L-serine, and glycine decrease with age. This process was most pronounced for D-serine concentrations, which decreased 4.9-fold (GC-MS) or 9.0-fold (LC-MS) during the first 3 years of life and remained constant thereafter (8). The age-dependent changes in CSF amino acids illustrate the potential need for differing interpretations of neonatal, prenatal, adolescent, and adult CSF concentrations. Fortunately the novel methods reported here (8) enable such differentiation and should be valuable tools for continued evaluation of the role of amino acids, including D-serine and L-serine, in investigating both normal brain function and the pathophysiology of various neuropsychiatric disorders.


Acknowledgments

Grant/Funding Support: None declared.

Financial Disclosures: None declared.


Footnotes

1 Nonstandard abbreviations: DAAO, D–amino acid oxidase; NMDA, N-methyl D- aspartate; CSF, cerebrospinal fluid.


References

  1. Corrigan JJ. D-Amino acids in animals. Science (Wash DC) 1969;164:141-149.
  2. Krebs HA. The D- and L-amino-acid oxidases. Biochem Soc Symp 1948;1:2-18.[Medline] [Order article via Infotrieve]
  3. Nagata Y, Yamamoto K, Shimojo T, Konno R, Yasumura Y, Akino T. The presence of free D-alanine, D-proline and D-serine in mice. Biochim Biophys Acta 1992;1115:208-211.[Medline] [Order article via Infotrieve]
  4. Hashimoto A, Nishikawa T, Oka T, Takahashi K. Endogenous D-serine in rat brain: N-methyl-D-aspartate receptor-related distribution and aging. J Neurochem 1993;60:783-786.[Web of Science][Medline] [Order article via Infotrieve]
  5. Schell MJ. The N-methyl D-aspartate receptor glycine site and D-serine metabolism: an evolutionary perspective. Phil Trans R Soc Lond B 2004;359:943-964.[Abstract/Free Full Text]
  6. Fukushima T, Kawai J, Imai K, Toyo'oka T. Simultaneous determination of D- and L-serine in rat brain microdialysis sample using a column-switching HPLC with fluorimetric detection. Biomed Chromatogr 2004;18:813-819.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  7. Sethuraman R, Krishnamoorthy MG, Lee TL, Liu EH, Chiang S, Nishimura W, et al. Simultaneous analysis of D- and L-serine in cerebrospinal fluid by use of HPLC. Clin Chem 2007;53:1489-1494.[Abstract/Free Full Text]
  8. Fuchs SA, de Sain-van der Velden MGM, de Barse MMJ, Roeleveld MW, Hendriks M, Dorland L, et al. Two mass-spectrometric techniques for quantifying serine enantiomers and glycine in cerebrospinal fluid: potential cofounders and age-dependent ranges. Clin Chemistry 2008;54:1443-1450.[Abstract/Free Full Text]
  9. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropharmacol Biol Psychiatry 2005;29:767-769.[CrossRef]
  10. Bendikov I, Nadri C, Amar S, Panizzutti R, De Miranda J, Wolosker H, et al. A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res 2007;90:41-51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  11. Fuchs SA, Dorland L, de Sain-van der Velden MG, Hendriks M, Klomp LW, Berger R, et al. D-serine in the developing human central nervous system. Ann Neurol 2006;60:476-480.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  12. Kim PM, Aizawa H, Kim PS, Huang AS, Wickramasinghe SR, Kashani AH, et al. Serine racemase: activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration. Proc Natl Acad Sci USA 2005;102:2105-2110.[Abstract/Free Full Text]
  13. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003;60:572-576.[Abstract/Free Full Text]
  14. Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Takao H, et al. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol Psychiatry 2005;57:1493-1503.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  15. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom L, Iyo M. Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry 2005;5:6.[CrossRef][Medline] [Order article via Infotrieve]




This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hashimoto, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hashimoto, K.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS